EUVIMEDEUVIMED entdecken
Leserbrief

Comment on ‘Clinical and Pathological Characteristics of Stage IV SMARCA4-Deficient Lung Cancer and the Efficacy of Immune Checkpoint Inhibitors’

M Tao

Clinical Oncology · 2026-08 · 56 · 104199

DOI: 10.1016/j.clon.2026.104199 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Oncology, 2026-08. Verfasst von M Tao. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Clinical Medical College of Zhejiang Chinese Medical University, No. 548 Binwen Road,…. Die Arbeit nennt 5 Literaturangaben. Gefördert von: Zhejiang Chinese Medical University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The First Clinical Medical College of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, Zhejiang, 310053, China. Electronic addr…

Förderung

  • Zhejiang Chinese Medical University

Zitieren

APA

Tao, M. (2026). Comment on ‘Clinical and Pathological Characteristics of Stage IV SMARCA4-Deficient Lung Cancer and the Efficacy of Immune Checkpoint Inhibitors’. Clinical Oncology, 56, 104199. https://doi.org/10.1016/j.clon.2026.104199

Vancouver

Tao M. Comment on ‘Clinical and Pathological Characteristics of Stage IV SMARCA4-Deficient Lung Cancer and the Efficacy of Immune Checkpoint Inhibitors’. Clinical Oncology. 2026;56:104199. doi:10.1016/j.clon.2026.104199

BibTeX
@article{Tao2026,
  author = {Tao, M},
  title = {Comment on ‘Clinical and Pathological Characteristics of Stage IV SMARCA4-Deficient Lung Cancer and the Efficacy of Immune Checkpoint Inhibitors’},
  journal = {Clinical Oncology},
  year = {2026},
  volume = {56},
  pages = {104199},
  doi = {10.1016/j.clon.2026.104199}
}
Kostenlos starten →